The landmark INTerpath-001 trial demonstrates that an mRNA-based vaccine combined with immunotherapy significantly reduces melanoma recurrence.

In a historic milestone for oncology, pharmaceutical giants Merck and Moderna announced on August 19–20, 2026, that their Phase 3 INTerpath-001 trial met its primary and key secondary endpoints. The trial evaluated an investigational individualized neoantigen therapy—an mRNA-based personalized cancer vaccine known as intismeran autogene (mRNA-4157)—in combination with Merck's blockbuster anti-PD-1 therapy KEYTRUDA (pembrolizumab). The trial targeted patients with completely resected stage IIB-IV melanoma, a high-risk population prone to cancer recurrence.

According to the joint announcement, the combination therapy demonstrated statistically significant and clinically meaningful improvements over KEYTRUDA monotherapy, which is the current standard of care. This marks the first late-stage success for an individualized mRNA-based therapeutic regimen in an adjuvant melanoma setting, solidifying the potential of mRNA technology to combat cancer.

Primary Endpoint Achieved: Significant improvement in Recurrence-Free Survival (RFS) compared to KEYTRUDA alone.
• Secondary Endpoint Achieved: Statistically significant extension of Distant Metastasis-Free Survival (DMFS).
• Target Population: Patients with high-risk stage IIB-IV melanoma post-complete surgical resection.
• Innovative Mechanism: Tailored vaccine designed to prime the patient's immune system to target unique tumor mutations.

This positive Phase 3 data represents a monumental step forward in our efforts to bring individualized medicine directly to cancer therapy. By training the patient's own immune system against the specific signature of their tumor, we are opening a new frontier in oncology.","attribution":"Joint Statement from Merck and Moderna Research Laboratories

The successful trial results sparked immediate enthusiasm across both scientific and financial sectors. Shares of both Merck and Moderna experienced significant gains in trading, and oncology experts are hailing the milestone as a potential gateway to treating other highly mutagenic solid tumors, including lung and colorectal cancers. This achievement vindicates years of research into personalized vaccines, which had previously faced skepticism regarding scalability and therapeutic efficacy.